Cytomegalovirus Infection after Renal Transplantation: Occurrence, Clinical Features, and the Cutoff for Antigenemia in a University Hospital in Brazil
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Cytomegalovirus (CMV) is the main infectious agent causative of morbidity and mortality in transplant recipients. This study aimed to describe the occurrence and clinical features of CMV infection, and the optimum antigenemia assay cutoff associated with symptomatic infection. Materials and Methods: This was a cohort study that investigated 87 patients undergoing renal transplantation. The patients were monitored with the CMV antigenemia assay performed weekly for the first 3 months post-transplantation and subsequently, when CMV infection was suspected clinically. Results: CMV infection was observed in 63.2% (55/87) of the recipients during the follow-up. Of the 65 episodes observed, 75% (49/65) occurred until 100 days after transplantation (D+100) and 25% (16/65) after D+100 with a median of 60 days. CMV infection was associated with age of the transplant recipients (P = 0.001) and use of deceased donor organ (P = 0.009). There were asymptomatic (34%) and symptomatic (66%) episodes of CMV infection, in which diarrhea was the most common symptom (22.6%), followed by elevated creatinine levels (14.5%), fever (12.9%) and leukopenia (10.5%). The optimum cutoff point associated with symptomatic infection was 5 positive cells/200,000 leukocytes (area under the curve = 0.87, positive predictive value = 88% and negative predictive value= 71%). Conclusion: The high occurrence and the risk factors for CMV infection such as the age of recipients, the number of positive cells in the antigenemia assay, and use of a deceased donor organ should be considered for appropriate monitoring and management of kidney recipients during the post-transplant period.
Abstract
Background: Cytomegalovirus (CMV) is the main infectious agent causative of morbidity and mortality in transplant recipients. This study aimed to describe the occurrence and clinical features of CMV infection, and the optimum antigenemia assay cutoff associated with symptomatic infection. Materials and Methods: This was a cohort study that investigated 87 patients undergoing renal transplantation. The patients were monitored with the CMV antigenemia assay performed weekly for the first 3 months post-transplantation and subsequently, when CMV infection was suspected clinically. Results: CMV infection was observed in 63.2% (55/87) of the recipients during the follow-up. Of the 65 episodes observed, 75% (49/65) occurred until 100 days after transplantation (D+100) and 25% (16/65) after D+100 with a median of 60 days. CMV infection was associated with age of the transplant recipients (P = 0.001) and use of deceased donor organ (P = 0.009). There were asymptomatic (34%) and symptomatic (66%) episodes of CMV infection, in which diarrhea was the most common symptom (22.6%), followed by elevated creatinine levels (14.5%), fever (12.9%) and leukopenia (10.5%). The optimum cutoff point associated with symptomatic infection was 5 positive cells/200,000 leukocytes (area under the curve = 0.87, positive predictive value = 88% and negative predictive value= 71%). Conclusion: The high occurrence and the risk factors for CMV infection such as the age of recipients, the number of positive cells in the antigenemia assay, and use of a deceased donor organ should be considered for appropriate monitoring and management of kidney recipients during the post-transplant period.
참고문헌 (20)
- Poornima Ramanan, "Cytomegalovirus Infections in Solid Organ Transplantation: A Review", Infection and Chemotherapy, 45(3), pp.260~271 (2013), 대한감염학회
- Browne BJ, "The impact of cytomegalovirus infection ≥1 year after primary renal transplantation", Clin Transplant, 24, pp.572~577 (2010)
- Cordero E, "Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors", Transplant Proc, 44, pp.694~700 (2012)
- Giakoustidis D, "Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center", Transplant Proc, 44, pp.2715~2717 (2012)
- Hughes D, "Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients", J Clin Virol, 41, pp.92~95 (2008)
- Jung GO, "The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation", Transplant Proc, 42, pp.804~810 (2010)
- De Keyzer K, "Human cytomegalovirus and kidney transplantation: a clinician's update", Am J Kidney Dis, 58, pp.118~126 (2011)
- Selvey LA, "Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience", BMC Infect Dis, 17, pp.501~ (2017)
- Andrews PA, "Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation", Transplant, 92, pp.1181~1187 (2011)
- Kotton CN, "Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation", Transplant, 89, pp.779~795 (2010)
- Fisher CE, "Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients", Clin Infect Dis, 65, pp.57~63 (2017)
- Kowalsky S, "Prevention of cytomegalovirus following solid organ transplantation: a literature review", Pediatr Transplant, 17, pp.499~509 (2013)
- Saracino A, "The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience", Transplant Proc, 45, pp.182~184 (2013)
- Atkinson C, "Cytomegalovirus quantification: where to next in optimising patient management?", J Clin Virol, 51, pp.223~228 (2011)
- Razonable RR, "Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation", Clin Microbiol Rev, 26, pp.703~727 (2013)
- Ljungman P, "Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials", Clin Infect Dis, 64, pp.87~91 (2017)
- Jamal AJ, "Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients", Transplant, 97, pp.569~575 (2014)
- Harvala H, "High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy", J Med Virol, 85, pp.893~898 (2013)
- Schröeder R, "Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease", Transplant Proc, 37, pp.2781~2783 (2005)
- Pilmore H, "KHA-CARI guideline: cytomegalovirus disease and kidney transplantation", Nephrol, 16, pp.683~687 (2011)